rucaparib + lucitanib

Rucaparib + lucitanib is an oral investigational combination therapy for advanced solid tumors. **Rucaparib** is a small molecule inhibitor of poly(ADP-ribose) polymerase (PARP) 1, 2, and 3, which impairs DNA repair in cancer cells, leading to cell death, particularly in tumors with homologous recombination repair (HRR) deficiencies. **Lucitanib** is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptors (VEGFR1–3), platelet-derived growth factor receptors (PDGFRα/β), and fibroblast growth factor receptors (FGFR1–3), exerting antiangiogenic and antiproliferative effects. Preclinical data suggest lucitanib may enhance antitumor activity of rucaparib through increased tumor hypoxia and sensitivity to PARP inhibition. The combination is being studied for tolerability, safety, and preliminary efficacy, with early results showing manageable toxicity and early evidence of disease stability in heavily pretreated patients with advanced solid tumors, including those with BRCA1/2, ATM, PALB2, RAD51B, and CDK12 mutations[1][3][9].